Suggested Readings

Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC) +dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.

Bosch B, Akpomiemie G, Chandiwana N, et al. Clin Infect Dis. 2022;ciac949. 

Long-acting injectables: current perspectives and future promise.

Chaudhary K, Patel MM, Mehta PJ. Crit Rev Ther Drug Carrier Syst. 2019;36(2):137-181.   

First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic.

Christopoulos KA, Grochowski J, Mayorga-Munoz F, et al. Clin Infect Dis. 2022; ciac631.

The management of treatment-experienced HIV patients (including virologic failure and switches).

Cutrell J, Jodlowski T, Bedimo R. Ther Adv Infectious Dis. 2020;7:2049936120901395. 

Type 2 diabetes prevalence and its risk factors in HIV: a cross-sectional study.

Duncan AD, Goff LM, Peters BS. PLoS One. 2018;13(3):e0194199. 

Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing.

Imbert E, Hickey MD, Clemenzi-Allen A, et al. AIDS. 2021;35(8). 

Beyond core indicators of retention in HIV care: Missed clinic visits are independently associated with all-cause mortality.

Mugavero MJ, Westfall AO, Cole SR, et al. Clin Infect Dis. 2014;59(10):1471-1479.

Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.

Neesgaard B, Greenberg L, Miró JM, et al. Lancet HIV. 2022;9(7):e474-e485.  

Treatment adherence mediates the relationship between HIV-related stigma and health-related quality of life.

Onu DU. AIDS Care. 2021;33(10):1335-1339.  

Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer.

Palefsky JM, Lee JY, Jay N, et al. N Engl J Med. 2022;386(24):2273-2282. 

Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV.

Paton NI, Musaazi J, Kityo C, et al. N Engl J Med. 2021;385(4):330-341. 

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Rodger AJ, Cambiano V, Bruun T, et al. Lancet. 2019;393(10189):2428-2438.  

Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.

Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1380-1390.

Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.

Shafran SD, Hughes CA. HIV Med. 2023;24(3):361-365. 

Linked Resources

Additional Activities in HIV

Answers to Everyday Practice Challenges in HIV Medicine: Volume 2 (A Phone-a-Friend Peer Consult Series)

Optimizing HIV and HCV Treatment and  Prevention Among People Experiencing Homelessness: An Expert Panel Discussion

Applying HIV Advances in Practice: What the Pharmacist Needs to Know

Clinical Practice Guidelines

Standard of Care in Diabetes – 2023

ElSayed NA, et al. Diabetes Care. 2023:45(Suppl 1):S1-S291. 

Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association.

Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA Panel.

Gandhi RT, Bedimo R, Hoy JF, et al. JAMA. 2023;329(1):63-84.

Clinical Guidelines Program

New York State Department of Health AIDS Institute 

Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

US Department of Health and Human Services 

Clinician Resources

ASCVD Risk Estimator Plus.

American College of Cardiology.

Ward 86 long-acting injectable antiretroviral protocol.

Getting to Zero San Francisco. 

HIV Drug Resistance Database

Stanford University.

Patient Health Questionnaire-2

University of Washington.   

Patient and Caregiver Resources

AIDSMap Resources

NAM Publications 

Resources for persons living with HIV

Centers for Disease Control and Prevention 

HIV resources

National Institutes of Health 

Motivational interviewing and HIV: a guide for navigators.

National Minority AIDS Council.  

Related activities
1.00 CME/CE

The HIV Journey

Staying the Course Through Critical Junctions in Care

Faculty: Onyema Ogbuagu, MBBCh, FACP, FIDSA
Release: 05/31/2023
Expiration: 05/30/2024